Janssen

Views & Analysis
Ben Wiegand

The science of prevention

'Prevention' might be the buzzword of the moment in the pharma industry, but what does it actually mean for a company to intercept diseases before they even present clinically?

Digital
Deep Dive Access and Commercialisation

Deep Dive: Access and Commercialisation

In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work with he

Views & Analysis
Kris Sterkens

Changing the shape of healthcare

Kris Sterkens, company group chairman of Janssen EMEA, explains why pharma needs to be part of the solution.